Skip to main content
. 2012 Jul 27;17(8):1014–1026. doi: 10.1634/theoncologist.2012-0043

Table 3.

Randomized, double-blind, placebo-controlled, phase IIb screening trials of sorafenib in HER2-negative advanced breast cancer

graphic file with name onc00812-1129-t03.jpg

Progression-free survival was the primary endpoint.

aOne-sided p value.

Abbreviations: AC, Accelerated Community Oncology Research; CI, confidence interval; FM, Fondazione Michelangelo; HR, hazard ratio; NU, Northwestern University; SOLTI, Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos.